Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
The acquisition of these assets represents a significant milestone for $PDGO, providing a
substantial increase in its portfolio and operational footprint. https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
The acquisition of these assets represents a significant milestone for $PDGO, providing a
substantial increase in its portfolio and operational footprint. https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
$BIDCF Buy Recommendation!
>>> https://wallstreetresearcher.com/News/A%20News%20BITK.html
$RONN Ronn Ford, the companies CEO, announced that RONN Inc. and H2H, along with its various partners globally, will sign a LOI to integrate and commercialize H2H's many hydrogen proprietary products, which include leading-edge proprietary hydrogen storage and hydrogen a/c systems. https://finance.yahoo.com/news/ronn-inc-agrees-h2h-integrate-121500419.html
$AGBA - Great Analysis - http://BestGrowthStocks.com Unveils In-Depth Review of Triller Merger with AGBA Group Holding Limited https://nasdaq.com/press-release/bestgrowthstocks.com-unveils-in-depth-review-of-triller-merger-with-agba-group
#stockstobuy #stockstowatch #bestgrowthstocks #AGBA
$BIDCF HUGE NEWS/UDPATE Are Imminent!
http://Blockchaink2.com
$FONU is set to redefine success in real estate. https://twitter.com/DACE0325/status/1780967288969068564
$BIDCF $BITK.V BlockchainK2 Announces Update on Strategic Investment in RealBlocks
New York, New York--(Newsfile Corp. - February 20, 2024) - BlockchainK2 Corp. (TSXV: BITK) (OTCQB: BIDCF) (FSE: KRL2) ("BlockchainK2" or the "Company") is pleased to announce an investment in Enverxergy Inc., commonly referred to as "RealBlocks", a modern investment platform bundling all front, and back-office capabilities needed by Asset Managers and Intermediaries to provide automated, efficient, and low cost global access to Alternative Investments. The Company will acquire a majority interest in RealBlocks.
https://finance.yahoo.com/news/blockchaink2-announces-strategic-investment-realblocks-070000511.html
$RONN RONN, Inc. Provides an Update to Its Previously Announced First Nations Canada Hydrogen Initiative https://finance.yahoo.com/news/ronn-inc-provides-previously-announced-124100113.html
i truly believe IBGR READY FOR BREAK OUT
With this acquisition, $PDGO is well-positioned to capitalize on emerging opportunities in the
energy market, driving value for its shareholders and contributing to the economic development
of the regions in which it operates. https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
$RONN, Inc. Agrees to Work with H2H to Integrate Their Patented Products into Ronn Inc. Global Projects
SCOTTSDALE, AZ / ACCESSWIRE / April 16, 2024 / Ronn, Inc (OTC PINK:RONN). Ronn Ford, the companies CEO, announced today that RONN Inc. and H2H, along with its various partners globally, will sign a LOI to integrate and commercialize H2H's many hydrogen proprietary products, which include leading-edge proprietary hydrogen storage and hydrogen a/c systems. Additionally, as they become available, the agreement details will be updated.
Mr. Ford added that our friends at H2H already have agreements with groups in India with whom we are presently developing commercial relationships and potential Joint Ventures. A partnership with H2H would potentially open doors for many of the groups they are already in relationships. We are very excited to integrate their patented hydrogen storage and hydrogen a/c systems. See more details about our friends at their latest link below.
https://www.lokmattimes.com/business/bses-game-changing-partnership-mercury-ev-tech-ventures-into-hydrogen-storage-manufacturing/
For media inquiries, please contact:
For more information, go to www.ronnmotorgroup.com or contact John Morgan at jmorgan@ronnmotorgroup.com
About RONN, Inc.
RONN, Inc. is a forward-thinking company dedicated to making a positive impact on the environmental credit market. With a commitment to innovation and sustainability in the commercialization of Hydrogen in both mobile and stationary sectors, RONN, Inc. strives to create value for both its shareholders and the planet.
https://finance.yahoo.com/news/ronn-inc-agrees-h2h-integrate-121500419.html
$BIDCF $BITK.V BlockchainK2 Announces Update on Strategic Investment in RealBlocks https://finance.yahoo.com/news/blockchaink2-announces-strategic-investment-realblocks-070000511.html
$PDGO Announces Acquisition of 100% Interest in 58 Oil and Gas Wells and 600 Acres of Land
in Oklahoma https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
$ADMQ ADM Endeavors Receives Final Building Permits for New Texas Facility
https://finance.yahoo.com/news/adm-endeavors-receives-final-building-110000434.html
$RVVTF Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder https://finance.yahoo.com/news/revive-therapeutics-provides-psilocybin-clinical-113000679.html
$IVDN News: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$BDPT loading zone!! trip zero play
$RONN GET SOME SHARES WHILE YOU CAN!!! HUGE UPDATES COMING VERY SOON....
1847 Holdings LLC (NASDAQ: EFSH) Looking Primed for a Bounce
Float approx. 5.92m
Current PPS $2.03
https://mailchi.mp/broadstreetalerts/efsh-breakout-alert-95653?e=
CSE: $TRUE, OTC: $TREIF A.I. is Making Healthcare Faster, Safer, and More Affordable https://www.thebullreport.com/true/
$EFSH looks primed $90m in revenues FY 2023 with spinoff/dividend in play. Tiny float 5.9m https://mailchi.mp/broadstreetalerts/efsh-breakout-alert?e=
Top 8 Reasons Why $TREIF cse $TRUE Should Be On Your Radar
click here >>> https://www.thebullreport.com/true/
Top 8 Reasons Why $TREIF cse $TRUE Should Be On Your Radar
click here >>> https://www.thebullreport.com/true/
$TREIF CSE $TRUE BREAKINGNEWS: Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html
$NICH -- Views of the exciting times at the Palm Beach International Boat Show. Tover tastings went well. Some great networking while allowing some high level individuals to taste what is to come.
Views of the exciting times at the Palm Beach International Boat Show. Tover tastings went well. Some great networking while allowing some high level individuals to taste what is to come. $NICH pic.twitter.com/zTBgYtLVWS
— Nitches (@nitchescorp) March 26, 2024
$RONN Motor Group, Inc. is a global zero-emission Hydrogen Fuel Cell automaker (FCV). https://ronnmotorgroup.com/visions
$TREIF Treatment.com AI Inc. offers investors a chance to participate in both the healthcare sector — a sector that makes up 11% of our GDP — and the medical AI space, one of the fastest-growing fields around. Speak with your trusted investment advisor to see if a potential high-growth medical AI company like TRUE makes sense for your portfolio.
$TREIF CSE : $TRUE Treatment.com AI Inc.'s AI Medical Information Support Platform Uses in the Objective Structured Clinical Examination
https://www.marketscreener.com/quote/stock/TREATMENT-COM-AI-INC-121607440/news/Treatment-com-AI-Inc-s-AI-Medical-Information-Support-Platform-Uses-in-the-Objective-Structured-Cli-46277030/
$TWOH Two Hands Corporation is a food distribution Company serving food service customers with digital enabled logistics capabilities. The Company is listed on the OTC and CSE under stock symbol TWOH
TMC could go to 59 or 100 bucks. Do some DD.
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
Feb. 13th News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
Stallion Uranium $STLNF - Uranium Exploration Company Focused In The Athabasca Basin, Drills Being Mobilized https://www.reddit.com/r/PennyStocksWatch/comments/1bfhu5q/stallion_uranium_stlnf_uranium_exploration/
CEO.CA caught up with Drew Zimmerman, CEO of Stallion Uranium $STUD | OTCQB: $STLNF to discuss the land package they’ve put together and the latest expansion, exploration plans, and differentiating themselves from other Athabasca players.
$AURI --SCAM ALERT...see the board
$TWOH Two Hands Corporation: Elevating Canada's Micro Merchant Wholesaler Landscape https://finance.yahoo.com/news/two-hands-corporation-elevating-canadas-130000053.html
$AURI Token Listing and Partnership With a Top 100 CoinMarketcap Exchange https://www.reddit.com/r/BreakoutStocks/comments/1bdzak7/auri_token_listing_and_partnership_with_a_top_100/
#IFBC $IFBC Dino Luzzi Energy Drink and King #Esport Set to Ignite the Gaming Scene at XMAS COMICS #ESPORTS PARTNERSHIP ENERGIZING DINO LUZZI’S INFLUENCE https://finance.yahoo.com/news/dino-luzzi-energy-drink-king-140000045.html
#IFBC $IFBC go out and get @DinoLuzzi Energy drink today. Better than redbull!! Also publicly traded in the #OTCMarkets https://amazon.com/Dino-Luzzi-Energy-Drink-Count/dp/B09K7Y5DG7/ref=mp_s_a_1_3?crid=3UN1C4GYG7J7C&dib=eyJ2IjoiMSJ9.C6gywbI76WpH-JDN9smYMM19f3yatXKfLyftKj_Y7fc.1BJ3N-mJfAFRwkftCh9K8IF162BApw9nMLjzK_IFuyk&dib_tag=se&keywords=dino+luzzi+energy+drink&qid=1709932292&sprefix=%2Caps%2C70&sr=8-3
$STUD | $STLNF Stallion Uranium CEO Drew Zimmerman's webinar with Red Cloud Financial Services where he discussed Stallion's #exploration of over 3,000 sq/km in the Athabasca Basin.
$TWOH, DEBT FREE AND READY TO MINGLE… https://twohandsgroup.com/blog/twoh-debt-free
Discover 2024's #1 Uranium Stock Pick - Stallion Uranium Corp (TSXV: STUD, OTCQB: $STLNF)!
$TWOH — SEIZING OPPORTUNITY AMIDST CHALLENGES: HOW TWO HANDS GROUP (TWOH) IS NAVIGATING RISING FOOD PRICES WITH STRATEGIC ACQUISITIONS
https://twohandsgroup.com/blog/twoh-seizing-opportunity
Italian Food and Beverage Corporation (OTC: $IFBC) is the owner and direct importer of Dino Luzzi Energy Drink, a premium, FDA-approved beverage crafted in Italy and imported to the U.S. In 2022, it made a strategic move to expand its presence in Italy by acquiring 51% of Can International to increase our revenue and further establish its brand in Spain and Switzerland. Key Investment Factors
Growing – Dino Luzzi grew revenues from $38,137 in 2021 to $128,430 in 2022. That’s a 238% increase YoY. This shows the product is in demand, and that demand is growing.
Taste – Dino Luzzi beats out the big guys in blind taste tests. That’s no small feat. While brand recognition remains strong
Expansion Plans – IFBC has developed a significant prime retail space in Western Beef, a New-York based grocer. With 22 warehouse style stores and locations across the Northeastern US (and a few Florida outlets), Dino Luzzi has plenty of shelves to grow into. Additionally, the company has recently partnered with Key Food Fresh and Iavarone Bros. Made in Italy, IFBC’s Energy Drink sets itself apart from the competition by being light, crisp, smooth and refreshing. Most of all, No Metallic After-taste. https://microcaps.com/a-ground-floor-opportunity-in-a-growing-energy-drink-company/
BestGrowthStocks.Com Issues Comprehensive Analysis of IonQ Inc $IONQ
click here>>> https://bit.ly/3Iypkc2
News just issued on $IONQ - BestGrowthStocks.Com Issues Comprehensive Analysis of IonQ Inc
Extensive comprehensive analysis of IonQ’s financial results, potential catalysts, share structure, cash position, quantum computing and AI synergies and much more. Click here>>> https://www.nasdaq.com/press-release/bestgrowthstocks.com-issues-comprehensive-analysis-of-ionq-inc-2024-03-11
NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Petros Pharmaceuticals Inc a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs.
Access this full analysis free: https://bit.ly/43axdxO
News just issued on $PTPI - BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
Extensive comprehensive analysis of Petros Pharma’s potential catalysts, share structure, potential outcomes from the FDA decision for STENDRA® (avanafil), and much more. Click here>>> https://www.nasdaq.com/press-release/bestgrowthstocks.com-issues-comprehensive-analysis-of-petros-pharmaceuticals-inc-2024
Followers
|
943
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
30289
|
Created
|
06/17/11
|
Type
|
Free
|
Moderator ~ Blue ~ | |||
Assistants doogdilinger balamidas MOMO vantillian CHIEF-RISES-ABOVE |
Posts Today
|
0
|
Posts (Total)
|
30289
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |